17

June

FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

June 16, 2021 at 3:50 PM EDT
— First precision therapy that specifically targets the primary driver of the disease —
— Durable clinical responses, including complete remissions, shown in patients with or without prior treatment —
— Full approval supported by robust efficacy and safety data from two clinical trials —
— Blueprint Medicines to host investor conference call and webcast today at 4:30 p.m. ET —

CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). For the first time, advanced SM patients can now receive a targeted therapy designed to potently and selectively inhibit D816V mutant KIT, the central driver of the disease. Read more HERE.

Victoria

Victoria has blogged 1610 posts